Share on StockTwits

NBF initiated coverage on shares of Knight Therapeutics (CVE:GUD) in a research note issued on Thursday. The firm set an “outperform” rating and a C$6.50 price target on the stock. NBF’s price target suggests a potential upside of 5.86% from the company’s current price.

Separately, analysts at National Bank Financial initiated coverage on shares of Knight Therapeutics in a research note on Thursday. They set an “outperform” rating and a C$6.50 price target on the stock.

Knight Therapeutics (CVE:GUD) traded up 1.90% on Thursday, hitting $5.36. The stock had a trading volume of 103,851 shares. Knight Therapeutics has a 52 week low of $3.51 and a 52 week high of $7.24. The stock’s 50-day moving average is $5.09 and its 200-day moving average is $5.41. The company’s market cap is $416.8 million.

Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.